DURHAM, N.C.–(BUSINESS WIRE)–
Tryton Medical, Inc., the leading developer of stents designed to treat coronary bifurcation lesions, today announced that the first U.S. commercial case using the Tryton Side Branch Stent to treat a coronary bifurcation lesion involving a large side branch (appropriate for a ≥2.5mm stent) was completed at New York-Presbyterian Hospital/Columbia University Medical Center in New York City. The procedure was performed by Martin Leon, MD, director of the Center for Interventional Vascular Therapy, and Ajay Kirtane, MD, SM, director of the Cardiac Catheterization Laboratory.
Approximately 20-30% of all patients undergoing percutaneous coronary interventions (PCI) to open blocked arteries have a bifurcation lesion. The Tryton Side Branch Stent recently became the first dedicated bifurcation device to receive regulatory approval in the U.S. Tryton has signed a strategic distribution agreement with Cardinal Health enabling Cordis, its interventional vascular business, to be the exclusive distributor of the Tryton Side Branch Stent in the U.S.
“Dr. Leon and the cath lab team at Columbia University Medical Center played an integral role investigating the Tryton Side Branch Stent through extensive clinical research leading to the recent FDA approval,” said Shawn McCarthy, president and CEO of Tryton Medical. “We are honored to have the team at Columbia perform the first U.S. commercial case and appreciate their guidance during the Tryton Clinical Trials and leadership they provide for the interventional community around the world. Tryton looks forward to working with Cordis to ensure interventional cardiologists in the U.S. have access to a dedicated bifurcation device.”
About Tryton Side Branch Stent
The Tryton Side Branch Stent System is built using proprietary Tri-ZONE® technology to offer a dedicated strategy for treating bifurcation lesions. Tryton’s cobalt chromium stent is deployed in the side branch artery using a standard single wire balloon-expandable stent delivery system. A conventional drug eluting stent is then placed in the main vessel. The Tryton Side Branch Stent has now been used to treat more than 12,000 patients worldwide. It is commercially available in multiple countries within Europe, the Middle East and Africa, and is approved for use in the U.S.
About Tryton Medical, Inc.
Tryton Medical, Inc., located in Durham, N.C., is the leading developer of novel stent systems for the treatment of bifurcation lesions. The company was founded in 2003 by Aaron V. Kaplan, M.D., professor of medicine at the Geisel School of Medicine/Dartmouth-Hitchcock Medical Center, to develop stents for the definitive treatment of bifurcation lesions. For more information please visit www.trytonmedical.com and follow the company on Twitter at @TrytonMedical1.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170321006583/en/
